THALES
15.9.2021 14:36:08 CEST | Business Wire | Press release
Contactless payment technology brings convenience to consumers worldwide, especially in the wake of the current pandemic. And, by bringing contactless payment devices to wearables to integrate more seamlessly into users’ daily lives. Thales, with its strong history in providing secure payment products to banks and other financial institutions, now takes this to wearable fashion in Japan.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210915005664/en/
The EVERING, an NFC ring, enables contactless payments working on a “Less is Smart” premise. The waterproof ceramic ring supports cashless and touchless payments, offering a seamless experience for users to pay when the ring is held in close proximity to the payment terminal. The waterproof battery-less ring requires no charging, and marries fashion with technology, with the convenience of contactless transactions.
Thales will provide both the secure embedded chip and Operating System as well as card personalisation services for the device, with EVERING as the Payment Card Issuer, enabling fast and secure contactless transactions on this ring. The payment data on the ring will be directly linked to customers’ prepaid bank accounts,. The payment personalisation services on the rings ensure optimal data management for EVERING. All integration and personalisation work on the rings will be undertaken by dedicated Thales teams in Asia, ensuring close collaboration with EVERING to meet the evolving needs of their end users.
“We are delighted to partner with EVERING, a company that is bridging technology and fashion with the launch of their contactless payment ring. Thales has a long history of providing digital identity and security solutions in Japan, notably in the area of mobile communications and banking services. This collaboration takes our commitment a step further as we work with an innovative start-up to support their customers in this fast-evolving payment ecosystem. With this partnership, Thales is accelerating our business development efforts with alternative payment issuers in Japan, including Fintech companies, as we continue to refine our technology for wearable devices,” Cyrille Dupont, Country Director, Thales in Japan
“Consumers in Japan acknowledge that contactless electronic transactions are the way forward, with rapid adoption accelerated by the pandemic. By combining aesthetics with functionality, and most importantly, security, the EVERING may well be a solution that can drive Japan towards becoming a cashless society. We decided to partner with Thales because of their proven track record in security and encryption technologies. With this partnership, we assure our customers that their financial transactions remain safe and secure and that the ring is equipped with international-standards of security technology,” Takeshi Kawada, Chief Executive Officer, EVERING
About Thales
Thales (Euronext Paris: HO) is a global leader in advanced technologies, investing in digital and “deep tech” innovations – connectivity, big data, artificial intelligence, cybersecurity and quantum computing – to build a confident future crucial for the development of our societies. The Group provides its customers – businesses, organisations and governments – in the defense, aeronautics, space, transport, and digital identity and security domains with solutions, services and products that help them fulfil their critical role, consideration for the individual being the driving force behind all decisions.
Thales has 81,000 employees in 68 countries. In 2020 the Group generated sales of €17 billion.
About Thales in Japan
Present in Japan since 1970, Thales works with over 500 partners ranging from large enterprises to SMEs. The Group serves Japanese needs in scientific, security and defence (Japanese government), aerospace, digital identity & security solutions (various Japanese organizations, MNOs, banks, governmental or civil markets), spatial, transportation and various industrial applications.
A strong portfolio of solutions and technologies enables Thales to meet customer and partner needs efficiently by supporting them in common projects. Key projects have enabled Thales in Japan to expand the business locally and to build a dynamic and skilled workforce.
With close to 150 employees in Japan, mainly in Tokyo, Thales’ ambition is to boost its local presence by partnering with strategic key industrial Japanese players and to address the needs of the local ecosystem.
About EVERING
Founded in February 2020 in Tokyo, EVERING is a high-technology company that strives to be truly smart, starting from payments to endless possibilities. The company adopts the philosophy of “ Simplicity in Design, Flawless Execution and Straightforward Functionality ” in its products, thereby enabling an intuitive, seamless and refined user experience. By focusing only on the necessary elements in its products and coupling with a sleek design aesthetic, EVERING brings a new level of technology and design to Japan.
PLEASE VISIT
Digital Identity & Security
Download HD photos
View source version on businesswire.com: https://www.businesswire.com/news/home/20210915005664/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release
REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release
In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release
- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c
Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press release
Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til
IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press release
Venneman brings more than 30 years of digital transformation, AI, and enterprise technology experience as IQM prepares for its planned Nasdaq listing IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
